Mary Grecco

Lung Cancers Today

SCLC is a rapidly progressing cancer that initially responds to first-line therapy but almost always relapses, and prognosis for these patients is poor due to limited second-line treatment options. Tarlatamab is a bispecific T-cell engager molecule that engages both CD3 on T cells and delta-like ligand 3 on SCLC cells, leading to T-cell-mediated lysis of SCLC cells.
Previous results from the phase 1 DeLLphi-300 study of tarlatamab in patients with heavily pretreated relapsed or refractory SCLC showed a manageable safety profile, along with antitumor activity and an encouraging response durability. This trial was followed by the phase 2, open-label DeLLphi-301 study that evaluated patients with advanced SCLC treated with a platinum-based regimen and one other line of therapy. Results from DeLLphi-301 and updated details of the phase 3 trial in progress were presented at the 2023 North America Conference on Lung Cancer.
Results from the phase 2 study showed that tarlatamab at a dose of 10 mg every 2 weeks demonstrated anticancer activity, with an overall response rate of 40% and a manageable safety profile in patients with previously treated SCLC. DeLLphi-304 is a global, open-label, randomized phase 3 trial that will evaluate the efficacy and safety of tarlatamab against SOC in approximately 700 patients with relapsed SCLC following platinum-based first-line chemotherapy, with a goal of providing clarity on long-term response durability and survival benefits.
Patients are randomized 1:1 to receive tarlatamab or SOC (lurbinectedin or topotecan or amrubicin per local SOC), stratified by prior anti-PD-L1 treatment, chemotherapy-free interval, presence of brain metastases, and SOC (topotecan/amrubicin vs lurbinectedin). The primary objective is to compare the efficacy of tarlatamab with SOC in prolonging OS. Key secondary end points include comparison of PFS and patient-reported outcomes. Eligibility criteria include adults with histologically or cytologically confirmed relapsed SCLC who progressed following one platinum-based regimen, along with measurable lesions per Response Evaluation Criteria in Solid Tumors 1.1 and adequate organ function. Enrollment is currently ongoing (NCT05060016).
Source: Paz-Ares L, Felip E, Ahn M-J, et al. Trial in progress: randomized phase 3 study of tarlatamab, a DLL3-targeting bispecific T-cell engager (BiTE), compared to standard of care in relapsed small cell lung cancer (DeLLphi-304). Abstract of a poster presented at the 2023 North America Conference on Lung Cancer; December 1-3, 2023; Chicago, Illinois.

SCLC is a rapidly progressing cancer that initially responds to first-line therapy but almost always relapses, and prognosis for these patients is poor due to limited second-line treatment options. Tarlatamab is a bispecific T-cell engager molecule that engages both CD3 on T cells and delta-like ligand 3 on SCLC cells, leading to T-cell-mediated lysis of SCLC cells.Previous results from the phase 1 DeLLphi-300 study of tarlatamab in patients with heavily pretreated relapsed or refractory SCLC showed a manageable safety profile, along with antitumor activity and an encouraging response durability. This trial was followed by the phase 2, open-label DeLLphi-301 study that evaluated patients with advanced SCLC treated with a platinum-based regimen and one other line of therapy. Results from DeLLphi-301 and updated details of the phase 3 trial in progress were presented at the 2023 North America Conference on Lung Cancer.Results from the phase 2 study showed that tarlatamab at a dose of 10 mg every 2 weeks demonstrated anticancer activity, with an overall response rate of 40% and a manageable safety profile in patients with previously treated SCLC. DeLLphi-304 is a global, open-label, randomized phase 3 trial that will evaluate the efficacy and safety of tarlatamab against SOC in approximately 700 patients with relapsed SCLC following platinum-based first-line chemotherapy, with a goal of providing clarity on long-term response durability and survival benefits.Patients are randomized 1:1 to receive tarlatamab or SOC (lurbinectedin or topotecan or amrubicin per local SOC), stratified by prior anti-PD-L1 treatment, chemotherapy-free interval, presence of brain metastases, and SOC (topotecan/amrubicin vs lurbinectedin). The primary objective is to compare the efficacy of tarlatamab with SOC in prolonging OS. Key secondary end points include comparison of PFS and patient-reported outcomes. Eligibility criteria include adults with histologically or cytologically confirmed relapsed SCLC who progressed following one platinum-based regimen, along with measurable lesions per Response Evaluation Criteria in Solid Tumors 1.1 and adequate organ function. Enrollment is currently ongoing (NCT05060016).Source: Paz-Ares L, Felip E, Ahn M-J, et al. Trial in progress: randomized phase 3 study of tarlatamab, a DLL3-targeting bispecific T-cell engager (BiTE), compared to standard of care in relapsed small cell lung cancer (DeLLphi-304). Abstract of a poster presented at the 2023 North America Conference on Lung Cancer; December 1-3, 2023; Chicago, Illinois.

Jessica Bauman, MD

Cecilia Brown

Virtual Palliative Care: Insights From the ASCO 2025 Update on the REACH PC Study

ASCO 2025

Stephen V. Liu, MD

ASCO 2025 Update on CheckMate 816: Stephen Liu, MD, Shares Insights

Jorge Nieva, MD

Should Immunotherapy Be Administered Earlier in the Day? Thoracic Oncologist Weights in on New ASCO 2025 Data

FDA Grants Accelerated Approval to Datopotamab Deruxtecan for EGFR-Positive NSCLC

EGFR+ NSCLC

Triparna Sen, PhD

Countering Immune Evasion in SCLC: Triparna Sen, PhD, Shares Insights on Drivers of MHC Repression

FDA Approval of Taletrectinib for ROS1+ NSCLC: Dr. Liu Weighs In

Non-Small Cell Lung Cancer

Latest News

Comparing the Standard of Care With Tarlatamab in Relapsed Small Cell Lung Cancer: DeLLphi-304